About The Study: This cohort study, including mostly patients with type 2 diabetes, does not show an association between use of glucagon-like peptide-1 (GLP-1) receptor agonists and an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders.
About The Study: This cohort study, including mostly patients with type 2 diabetes, does not show an association between use of glucagon-like peptide-1 (GLP-1) receptor agonists and an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders.
Corresponding Author: To contact the corresponding author, Peter Ueda, MD, PhD, email peter.ueda@ki.se.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamainternmed.2024.4369)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA Internal Medicine
Cite Scienmag News
Drew Townsend. (September 3, 2024). GLP-1 receptor agonist use and risk of suicide death. Scienmag. https://scienmag.com/glp-1-receptor-agonist-use-and-risk-of-suicide-death/
Drew Townsend. "GLP-1 receptor agonist use and risk of suicide death." Scienmag, 3 September 2024, https://scienmag.com/glp-1-receptor-agonist-use-and-risk-of-suicide-death/. Accessed 4 September 2026.
Drew Townsend. "GLP-1 receptor agonist use and risk of suicide death." Scienmag. September 3, 2024. https://scienmag.com/glp-1-receptor-agonist-use-and-risk-of-suicide-death/
